United Therapeutics Corp

UTHR

$181.93

+63.4% (1 year change)

Market Cap

$8.25 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$98.37 - $212.62

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

20.36x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $8.25 Billion
Enterprise Value $7.32 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +63.4%
52-Week High $212.62
52-Week Low $98.37
Beta 0.64
Outstanding Shares 44.8 Million
Avg 30 Day Volume 219 Thousand

Valuation

P/E Ratio 20.36
PEG -25.62
Earnings per Share $8.97
Price to Sales Ratio 5.51
Price to Book Ratio 2.39
Revenue to Enterprise Value 4.86
EBIT to Enterprise Value 20.22
Total Debt to Enterprise Value 0.11
Debt to Equity 0.23

Profitability

Revenue $1.51 Billion
Gross Profit $1.4 Billion
EBIT $362 Million
Net Income $405 Million
Profit Margin 26.92%
Quarterly Earnings Growth (YoY) -79.4%
Return on Equity 11.77%
Return on Assets 8.74%
Return on Invested Capital 8.35%

United Therapeutics Corp

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

News

Prostacyclin Drug Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:United Therapeutics, Teva, Actelion (J & J), Bayer AG, GSK, Tide Pharma, Toray

Prostacyclin Drug Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:United Therapeutics, Teva, Actelion (J & J), Bayer AG, GSK, Tide Pharma, Toray

This report studies the Prostacyclin Drug Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on comp...

Jumbo News Jumbo News, 6 days ago
Global Prostacyclin Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: United Therapeutics, Teva, Actelion (J & J), Bayer AG, GSK, Tide Pharma, Toray

Global Prostacyclin Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: United Therapeutics, Teva, Actelion (J & J), Bayer AG, GSK, Tide Pharma, Toray

The report on Global Prostacyclin Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this re...

Jumbo News Jumbo News, 8 days ago
United Therapeutics Stock Is Believed To Be Significantly Overvalued

United Therapeutics Stock Is Believed To Be Significantly Overvalued

Related Stocks: UTHR ,

GuruFocus GuruFocus, 18 days ago